Skip to main content

Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy

  • The original article was published in Journal of Experimental & Clinical Cancer Research 2020 39:8

Correction to: J Exp Clin Cancer Res (2020) 39:8.

https://doi.org/10.1186/s13046-019-1517-0

In the original publication of this manuscript [1], Fig. 1 contained a typographical error (‘Metabolic’ incorrectly written as ‘Metabolig’). The caption for Fig. 1 also contained typographical errors; “… regulated via O2-independent mechanisms.” should be instead have read “… regulated by O2-dependent mechanisms.”, and the caption should refer to 25 years and not 15 years. Figure 1 and its caption have now been corrected and are shown below.

Fig. 1
figure1

Schematic representation of the effects of intratumoral hypoxia in human diseases. a Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein that consists of a constitutively expressed HIF-1β subunit and a HIF-1α subunit regulated by O2-dependent mechanisms. Activated HIF-1 transcription factor binds to the hypoxia response elements (HRE) to induce transcription of, among others, target genes involved in angiogenesis, glucose metabolism, cell proliferation/survival, and invasion/metastasis. b Schematic representation of the number of scientific papers related to HIF-1, published in the last 25 years, and the relative diseases

In addition, the following sentences have been adjusted to remove ambiguity and correct the record:

‘Background’ section, “Hypoxia Inducible Factor-1 (HIF-1), is an α/β heterodimeric transcription factor that controls multiple oxygen-sensitive genes. In 1995 Semenza identified HIF-1α as a basic-helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension” has been corrected to “In 1995, Semenza identified the Hypoxia Inducible Factor-1 (HIF-1) as a basic-helix-loop-helix-PAS α/β heterodimeric transcription factor regulated by cellular oxygen tension.”

‘Background’ section, “… as evidenced by the increased number of papers published on this topic in the last 15 years” has been corrected to “… as evidenced by the increased number of papers published on this topic in the last 25 years.”

The authors sincerely apologize for the inconvenience caused to the readers. The original article has been updated.

Reference

  1. 1.

    Bosco MC, et al. Targeting hypoxia in tumor: a new promising therapeutic strategy. Journal of Experimental & Clinical Cancer Research. 2020;39:8.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gabriella D’. Orazi.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bosco, M.C., Orazi, G.D. & Del Bufalo, D. Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy. J Exp Clin Cancer Res 39, 43 (2020). https://doi.org/10.1186/s13046-020-1532-1

Download citation